Immunologic factors in primary progressive multiple sclerosis

Multiple Sclerosis

Volumn 10, Issue SUPPL. 1, 2004, Pages

  Hohlfeld, Reinhard ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Autoimmune disease; Glatiramer acetate; Multiple sclerosis; Neuroprotection

Indexed keywords

ALPHA4 INTEGRIN; BETA1 INTEGRIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; GAMMA INTERFERON; GLATIRAMER; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 4; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NITRIC OXIDE; SELECTIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL SELECTION; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOCOMPETENT CELL; LABORATORY DIAGNOSIS; MULTIPLE SCLEROSIS; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TH1 CELL; TH2 CELL;

EID: 3042646129     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms1026oa     Document Type: Article

References (13)

1. + T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000; 192: 393-404.
2. + T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci USA 2004; 101: 2428-33.
3. Thompson AJ, Montalban X, Barkhof F, Brochet B, Filippi M, Miller BH, et al. Primary/progressive multiple sclerosis: new diagnostic criteria. Ann Neurol 2000; 47: 831-35.
4. Egg R, Reindl M, Deisenhammer F, Linington C, Berger T. Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis. Multiple Sclerosis 2001; 7: 285-89.
5. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349: 139-45.
6. van Boxel-Dezaire AHH, Smits M, van Trigt-Hoff SCJ, Killestein J, van Houwelingen JC, Polman CH, et al. Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis. J Neuroimmunol 2001; 120: 152-60.
7. Peltola J, Ukkonen M, Moilanen E, Elovaara I. Increased nitric oxide products in CSF in primary progressive MS may reflect brain atrophy. Neurology 2001; 57: 895-96.
8. Durán I, Martínez-Cáceres EM, Río J, Barberá N, Marzo ME, Montalban X. Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules. Brain 1999; 122: 2297-307.
9. Martínez-Cáceres EM, Espejo C, Brieva L, Pericot I, Tintore M, Saez-Tores I, et al. Expression of chemokine receptors in the different clinical forms of multiple sclerosis. Multiple Sclerosis 2002; 8: 390-95.
10. Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999; 189: 865-70.
11. Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 2003; 53: 292-304.
12. Stadelmann C, Kerschensteiner M, Misgeld T, Brück W, Hohlfeld R, Lassmann H. BDNF and gpl45trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 2002; 125: 75-85.
13. Ziemssen T, Kümpfel T, Klinkert WEF, Neuhaus O, Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain 2002; 125: 2381-91.